255 related articles for article (PubMed ID: 24098507)
1. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
2. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
3. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
4. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
5. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
6. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
7. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
Kidd M; Siddique ZL; Drozdov I; Gustafsson BI; Camp RL; Black JW; Boyce M; Modlin IM
Regul Pept; 2010 Jun; 162(1-3):52-60. PubMed ID: 20144901
[TBL] [Abstract][Full Text] [Related]
8. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
Boyce M; Warrington S
Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
[TBL] [Abstract][Full Text] [Related]
9. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
10. The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.
Sagatun L; Mjønes P; Jianu CS; Boyce M; Waldum HL; Fossmark R
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1345-1352. PubMed ID: 27682220
[TBL] [Abstract][Full Text] [Related]
11. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
12. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours.
Murugesan SV; Steele IA; Dimaline R; Poston GJ; Shrotri M; Campbell F; Varro A; Pritchard DM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):474-81. PubMed ID: 23249603
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical indications for a CCK
Boyce M; Lloyd KA; Pritchard DM
Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
[TBL] [Abstract][Full Text] [Related]
14. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
Boyce M; Thomsen L
Scand J Gastroenterol; 2015 May; 50(5):550-9. PubMed ID: 25665655
[TBL] [Abstract][Full Text] [Related]
15. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
[TBL] [Abstract][Full Text] [Related]
16. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
[TBL] [Abstract][Full Text] [Related]
17. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
19. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
Ding XQ; Lindström E; Håkanson R
Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
[TBL] [Abstract][Full Text] [Related]
20. The gastric mucosa 25 years after proximal gastric vagotomy.
Sagatun L; Jianu CS; Fossmark R; Mårvik R; Nordrum IS; Waldum HL
Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]